http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104524595-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107 |
| filingDate | 2015-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104524595-B |
| titleOfInvention | A kind of resveratrol polymer bond drug and preparation method thereof |
| abstract | The present invention discloses a kind of high molecular polymer resveratrol bonding medicine and preparation method thereof.The resveratrol polymer bond drug has below general formula：P‑RES’ m Wherein：P is high molecular weight water soluble polymer, and m is the integer in 1~50；RES ' is Verakanol derivative, and the Verakanol derivative is made up of resveratrol and acyl chlorides.The polymer bond drug of the present invention has good hydrophily and biocompatibility, human body reticuloendothelial system phagocytic in blood circulation can be avoided, ensure to have the time of abundance to reach tumor locus by EPR effects, and then cell, the efficient targeting of Experimental agents are entered by endocytosis. |
| priorityDate | 2015-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 62.